Adeshwar Meditex Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 26, 2025, 10:08 pm

Quick Insight

Adeshwar Meditex Ltd, operating in the Medical Equipment & Accessories industry, currently shows promising fundamentals with a Price-to-Earnings ratio of 12.8, Return on Equity at 5.76%, and Return on Capital Employed at 8.39%. The company's Operating Profit Margin stands at 5.82%, reflecting operational efficiency. Notably, the firm's Intrinsic Value is 18.3, suggesting potential undervaluation. With a comfortable Interest Coverage Ratio of 3.47x and a Price-to-Book Value of 0.65x, Adeshwar Meditex Ltd appears financially stable. However, the lack of information on major shareholders raises transparency concerns. Investors should closely monitor developments in this stock to capitalize on its growth potential.

Competitors of Adeshwar Meditex Ltd

All Competitor Stocks of Adeshwar Meditex Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:10 am

Below is a detailed analysis of the quarterly data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 37.45 Cr.. The value appears to be declining and may need further review. It has decreased from 40.90 Cr. (Sep 2024) to 37.45 Cr., marking a decrease of 3.45 Cr..
• For Expenses, as of Mar 2025, the value is 35.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.90 Cr. (Sep 2024) to 35.27 Cr., marking a decrease of 3.63 Cr..
• For Operating Profit, as of Mar 2025, the value is 2.18 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 2.18 Cr., marking an increase of 0.18 Cr..
• For OPM %, as of Mar 2025, the value is 5.82%. The value appears strong and on an upward trend. It has increased from 4.89% (Sep 2024) to 5.82%, marking an increase of 0.93%.
• For Other Income, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.04 Cr..
• For Interest, as of Mar 2025, the value is 0.31 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.71 Cr. (Sep 2024) to 0.31 Cr., marking a decrease of 0.40 Cr..
• For Depreciation, as of Mar 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.25 Cr. (Sep 2024) to 0.21 Cr., marking a decrease of 0.04 Cr..
• For Profit before tax, as of Mar 2025, the value is 1.83 Cr.. The value appears strong and on an upward trend. It has increased from 1.25 Cr. (Sep 2024) to 1.83 Cr., marking an increase of 0.58 Cr..
• For Tax %, as of Mar 2025, the value is 27.32%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Sep 2024) to 27.32%, marking a decrease of 0.68%.
• For Net Profit, as of Mar 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.90 Cr. (Sep 2024) to 1.34 Cr., marking an increase of 0.44 Cr..
• For EPS in Rs, as of Mar 2025, the value is 0.93. The value appears strong and on an upward trend. It has increased from 0.62 (Sep 2024) to 0.93, marking an increase of 0.31.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:15 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:59 pm

Below is a detailed analysis of the balance sheet data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.43 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.43 Cr..
• For Reserves, as of Mar 2025, the value is 22.53 Cr.. The value appears strong and on an upward trend. It has increased from 20.48 Cr. (Mar 2024) to 22.53 Cr., marking an increase of 2.05 Cr..
• For Borrowings, as of Mar 2025, the value is 12.46 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.89 Cr. (Mar 2024) to 12.46 Cr., marking a decrease of 1.43 Cr..
• For Other Liabilities, as of Mar 2025, the value is 22.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.23 Cr. (Mar 2024) to 22.78 Cr., marking an increase of 7.55 Cr..
• For Total Liabilities, as of Mar 2025, the value is 72.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2.95 Cr.. The value appears to be declining and may need further review. It has decreased from 3.53 Cr. (Mar 2024) to 2.95 Cr., marking a decrease of 0.58 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.10 Cr..
• For Other Assets, as of Mar 2025, the value is 69.25 Cr.. The value appears strong and on an upward trend. It has increased from 60.40 Cr. (Mar 2024) to 69.25 Cr., marking an increase of 8.85 Cr..
• For Total Assets, as of Mar 2025, the value is 72.20 Cr.. The value appears strong and on an upward trend. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..

Notably, the Reserves (22.53 Cr.) exceed the Borrowings (12.46 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Adeshwar Meditex Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
• For Diluted EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.64. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 24) to 1.64, marking a decrease of 0.17.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 58.01. It has increased from 55.33 (Mar 24) to 58.01, marking an increase of 2.68.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 3.21. This value is within the healthy range. It has decreased from 3.68 (Mar 24) to 3.21, marking a decrease of 0.47.
• For PBIT / Share (Rs.), as of Mar 25, the value is 2.86. This value is within the healthy range. It has decreased from 3.26 (Mar 24) to 2.86, marking a decrease of 0.40.
• For PBT / Share (Rs.), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 1.94, marking an increase of 0.01.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 2. It has decreased from 1.39 (Mar 24) to 1.30, marking a decrease of 0.09.
• For PBDIT Margin (%), as of Mar 25, the value is 5.52. This value is below the healthy minimum of 10. It has decreased from 6.64 (Mar 24) to 5.52, marking a decrease of 1.12.
• For PBIT Margin (%), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 10. It has decreased from 5.89 (Mar 24) to 4.93, marking a decrease of 0.96.
• For PBT Margin (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 3.48 (Mar 24) to 3.33, marking a decrease of 0.15.
• For Net Profit Margin (%), as of Mar 25, the value is 2.23. This value is below the healthy minimum of 5. It has decreased from 2.51 (Mar 24) to 2.23, marking a decrease of 0.28.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.06. This value is below the healthy minimum of 15. It has decreased from 5.75 (Mar 24) to 5.06, marking a decrease of 0.69.
• For Return on Capital Employeed (%), as of Mar 25, the value is 10.49. This value is within the healthy range. It has decreased from 12.96 (Mar 24) to 10.49, marking a decrease of 2.47.
• For Return On Assets (%), as of Mar 25, the value is 2.59. This value is below the healthy minimum of 5. It has decreased from 3.13 (Mar 24) to 2.59, marking a decrease of 0.54.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.23. It has increased from 1.22 (Mar 24) to 1.23, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 2.03. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 2.03, marking a decrease of 0.03.
• For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.10 (Mar 24) to 1.25, marking an increase of 0.15.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 4. It has decreased from 2.86 (Mar 24) to 2.81, marking a decrease of 0.05.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.47. This value is within the healthy range. It has increased from 2.76 (Mar 24) to 3.47, marking an increase of 0.71.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.40. This value is below the healthy minimum of 3. It has increased from 2.04 (Mar 24) to 2.40, marking an increase of 0.36.
• For Enterprise Value (Cr.), as of Mar 25, the value is 33.89. It has decreased from 60.21 (Mar 24) to 33.89, marking a decrease of 26.32.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.40, marking a decrease of 0.35.
• For EV / EBITDA (X), as of Mar 25, the value is 7.33. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 7.33, marking a decrease of 4.01.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
• For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 24) to 0.65, marking a decrease of 0.71.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
• For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.07, marking an increase of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness